Sandra A Filla

age ~58

from Franklin, IN

Get Report

Also known as:

Connected to:

Sandra Filla Phones & Addresses

5-Ht1F Agonists
view source
US Patent:

6358972, Mar 19, 2002
Filed:

Dec 5, 2000
Appl. No.:

09/701934
Inventors:

Sandra Ann Filla - Franklin IN
Daniel James Koch - Indianapolis IN
Brian Michael Mathes - Indianapolis IN
Vincent Patrick Rocco - Indianapolis IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K 31435
US Classification:

514300, 546113
Abstract:

The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT receptors and inhibiting protein extravasation in a mammal.

Selective Iglur5 Receptor Antagonists For The Treatment Of Migraine
view source
US Patent:

6566370, May 20, 2003
Filed:

Dec 11, 2001
Appl. No.:

10/009655
Inventors:

David Bleakman - Zionsville IN
Sandra Ann Filla - Franklin IN
Kirk Willis Johnson - Carmel IN
Paul Leslie Ornstein - Carmel IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D21712
US Classification:

514307, 546147
Abstract:

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR receptor antagonist. The present invention further provides novel compounds functional as selective iGluR receptor antagonists as well as compositions and formulations comprising said selective iGluR receptor antagonists.

5-Ht1F Agonists
view source
US Patent:

6696439, Feb 24, 2004
Filed:

Aug 1, 2001
Appl. No.:

09/890720
Inventors:

Sandra Ann Filla - Franklin IN
Brian Michael Mathes - Indianapolis IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D49104
US Classification:

5142282, 5142338, 51425218, 514302, 544 61, 544127, 544362, 546115
Abstract:

The present invention relates to substituted furo[3,2-b]pyridine compounds of formula I: or a pharmaceutical acid addition salt thereof; where; R is EâD is C CH or CHâCH ; R is hydrogen or C -C alkyl; R is hydrogen, halo, hydroxy, âNR R , âSR , âC(O)R , âC(O)MR R , âNR SO R , âNHC(Q)NR R , âNHC(O)OR , or âNR C(O)R ; R , R , and R are independently hydrogen, C -C alkyl, C -C alkenyl, C -C alkynyl, or â(CH ) aryl; or R and R combine, together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine, or thiomorpholine ring; n is 0, 1, 2, 3, 4, 5, or 6; and Q is O or S. The present invention further relates to pharmaceutical. formulations containing compounds formula I and to the use of compounds of formula I for activating 5-HT receptors, inhibiting neuronal protein extravasation, and treating and/or preventing migraine in a mammal.

Selective Iglur5 Receptor Antagonists For The Treatment Of Neurological Disorders
view source
US Patent:

6759418, Jul 6, 2004
Filed:

Mar 6, 2003
Appl. No.:

10/383296
Inventors:

Sandra Ann Filla - Franklin IN
Paul Leslie Ornstein - Carmel IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D21712
US Classification:

514307, 546147
Abstract:

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR receptor antagonist. The present invention further provides novel compounds functional as selective iGluR receptor antagonists as well as compositions and formulations comprising said selective iGluR rec antagonists.

Excitatory Amino Acid Receptor Antagonists
view source
US Patent:

6855725, Feb 15, 2005
Filed:

Dec 20, 2001
Appl. No.:

10/451820
Inventors:

Thomas John Bleisch - Noblesville IN, US
Sandra Ann Filla - Ashland MA, US
Paul Leslie Ornstein - Carmel IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K031/47
C07D217/06
C07D401/00
US Classification:

514307, 546147, 546148
Abstract:

The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.

Selective Iglur5 Receptor Antagonists
view source
US Patent:

6855823, Feb 15, 2005
Filed:

Apr 9, 2004
Appl. No.:

10/821698
Inventors:

Sandra Ann Filla - Franklin IN, US
Paul Leslie Ornstein - Carmel IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D217/12
US Classification:

546147
Abstract:

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluRreceptor antagonist. The present invention further provides novel compounds functional as selective iGluRreceptor antagonists as well as compositions and formulations comprising said selective iGluRreceptor antagonists.

Excitatory Amino Acid Receptor Antagonists
view source
US Patent:

6953805, Oct 11, 2005
Filed:

Dec 20, 2001
Appl. No.:

10/451819
Inventors:

Sandra Ann Filla - Ashland MA, US
Kevin John Hudziak - Indianapolis IN, US
Brian Michael Mathes - Indianapolis IN, US
Paul Leslie Ornstein - Carmel IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D401/04
A61K031/47
US Classification:

514307, 546307
Abstract:

The present invention provides novel compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II in combination with a suitable carrier, diluent, or excipient, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.

Selective Iglurreceptor Antagonists
view source
US Patent:

7157582, Jan 2, 2007
Filed:

Jan 11, 2005
Appl. No.:

11/032759
Inventors:

Sandra Ann Filla - Franklin IN, US
Paul Leslie Ornstein - Carmel IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D 217/12
US Classification:

546147
Abstract:

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluRreceptor antagonist. The present invention further provides novel compounds functional as selective iGluRreceptor antagonists as well as compositions and formulations comprising said selective iGluRreceptor antagonists.